RIPK1 and neoplasm: Another study confirmed that RIPK1 and RIPK3 may be highly expressed in tumor-reactive T cells and undergo necrosis upon restimulation of the T cell receptor (TCR) with cognate antigen, which can be inhibited via RIPK1 inhibition [72, 73].